Breaking News

You are here » Indian-Commodity  :  Top News  :  USFDA advisory committee approves Mylan, Biocon's proposed biosimilar Trastuzumab

14-Jul2017

USFDA advisory committee approves Mylan, Biocon's proposed biosimilar Trastuzumab

The US Food and Drug Administration (USFDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin, which include HER2-positive breast cancer in the metastatic and adjuvant settings.

Mylan and Biocon's proposed biosimilar trastuzumab is also under review by regulatory authorities in Australia, Canada, Europe and several emerging markets.

Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products. The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.



Related News

View all news

Crude oil futures end lower on Friday

Crude oil futures ended lower on Friday on concerns about global energy demand. However, US prices managed to tally a gain for the week, their third in a row, as OPEC output cuts and US sanctions on Venezuela......

Gold futures finish higher on Friday

Gold futures finished higher on Friday, due to increased safe haven buying of market participants followed by subdued economic data from the euro zone, exacerbating global growth fears. Gold futures for......

Copper futures end lower on global growth concerns

Copper futures ended lower on Friday as weak European and US factory data spread gloom about the global economic outlook and strengthened the dollar. Reports showing Factory activity in the 19-country......

Top News

View all news

Infosys to enter into agreement with The House Fund II

Infosys is going to enter into an agreement with The House Fund II, L.P., an AI-focused fund targeting startups from the University of California - Berkeley, committing to invest $10.0 million.......

EID Parry receives approval for investment Rs 70 crore in PSRIPL

EID Parry (INDIA) has received approval for investment upto Rs 70 crore in the equity share capital of Parry Sugars Refinery India (PSRIPL), a wholly owned subsidiary of the Company. The Board of directors......

SBI raises Rs 1,251 crore by issuing Basel III-compliant bonds

State Bank of India (SBI) has raised Rs 1,251.30 crore by issuing Basel III-compliant bonds. The Committee of Directors for Capital Raising at its meeting held on 22 March 2019 deliberated and accorded......